Life Sciences Industry Seeks Targeted Reforms in Union Budget 2026

India’s life sciences sector is calling for focused policy support in Union Budget 2026 to strengthen manufacturing, innovation, and global competitiveness. Industry leaders have stressed the need for continuity in PLI-led initiatives, greater self-reliance in active pharmaceutical ingredients (APIs), and measures to boost exports. While schemes such as PLI and PRIP have created a strong base, the next phase must prioritise scale, execution, and cost efficiency.

Key demands include rationalising import duties on essential raw materials, targeted incentives for value-added formulations, stronger tax benefits for R&D, faster depreciation for compliance investments, and improved access to export credit. The nutraceutical industry is seeking a clearer regulatory framework and clinical validation to fully benefit from PLI support.

Healthcare stakeholders have also highlighted the importance of sustained funding for mental health, correction of inverted GST structures for medical devices, reduced import dependence, and dedicated cybersecurity funding as digital health adoption grows. Together, these reforms could help the sector reach its $120–130 billion goal by 2030.

14-01-2026